Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.

Hepatology (Baltimore, Md.) - 1 Feb 2021

Lu Ligong, Jiang Jun, Zhan Meixiao, Zhang Hui, Wang Qian-Ting, Sun Sheng-Nan, Guo Xiao-Kai, Yin Hua, Wei Yadong, Li Shi-You, Liu Jun O, Li Yong, He You-Wen

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Antineoplastic Agents, Immunological
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Disease-Free Survival

Share to Immunotherapy

Share to Neoplasm Recurrence, Local

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 32767586
DOI: 10.1002/hep.31502

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.PMID 32767586Read ↗

Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?Semantic proximity Read ↗

Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.Semantic proximity Read ↗

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.Semantic proximity Read ↗

Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.Semantic proximity Read ↗

Targeted therapy for hepatocellular carcinoma: Challenges and opportunitiesSemantic proximity Read ↗

New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinomaSemantic proximity Read ↗

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents.Semantic proximity Read ↗

Exploration of Practical Biomarkers for Systemic Drug Therapy for Hepatocellular CarcinomaSemantic proximity Read ↗

Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and BenefitSemantic proximity Read ↗

The perplexity of targeting genetic alterations in hepatocellular carcinoma.Semantic proximity Read ↗

Targeting hepatocellular carcinoma with aptamers: from biomarker detection to therapeutic applicationsSemantic proximity Read ↗

Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.